AEON Biopharma (AEON) Accumulated Expenses (2022 - 2026)

AEON Biopharma has reported Accumulated Expenses for 4 years, with the latest figure at $2.9 million in Q4 2025.

• Quarterly Accumulated Expenses rose 168.91% year-over-year to $2.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.9 million (up 168.91% YoY) and the FY2025 annual result came in at $2.9 million, up 168.91% from the prior year.
• Accumulated Expenses climbed to $2.9 million in Q4 2025 per AEON's latest filing, from $1.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.9 million in Q4 2025 and troughed at $429000.0 in Q1 2025.
• A 4-year average of $1.2 million and a median of $1.1 million in 2022 frame the typical range for Accumulated Expenses.
• The widest YoY moves for Accumulated Expenses: up 168.91% in 2025, down 67.94% in 2025.
• Over 4 years, Accumulated Expenses stood at $1.1 million in 2022, then slipped by 15.2% to $943000.0 in 2023, then climbed by 13.26% to $1.1 million in 2024, then soared by 168.91% to $2.9 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $2.9 million, $1.5 million, and $546000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.